MoonLake Immunotherapeutics
MLTX
$17.80
-$0.20-1.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.66% | 10.47% | -26.27% | -38.25% | 12.41% |
| Total Depreciation and Amortization | 12.52% | 0.81% | 0.40% | 96.30% | 3.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 379.42% | -4.39% | 164.32% | -36.60% | 167.91% |
| Change in Net Operating Assets | -186,966.67% | -99.97% | 1,902.35% | -222.22% | 90.54% |
| Cash from Operations | -12.74% | -31.99% | 18.31% | -42.97% | 21.32% |
| Capital Expenditure | -- | -- | -- | 100.00% | 80.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.33% | -133.83% | 0.17% | 56.81% | 138.25% |
| Cash from Investing | 100.33% | -133.83% | 0.17% | 56.91% | 138.18% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.47% | 14,982.29% | -- | -100.00% | -33.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -57.67% | 14,982.29% | -- | -100.00% | 48,325.17% |
| Foreign Exchange rate Adjustments | -630.77% | 131.93% | -120.49% | 1,680.68% | -120.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.13% | -136.82% | 25.46% | -61.47% | 146.68% |